Douglas J. Jolly

6.3k citations

108 papers · 4.8k indexed · 1 hit paper · h-index 37

Molecular Biology top 2%
Genetics top 0.5%
Oncology top 5%
Epidemiology top 5%
Immunology top 5%

Co-authors: Theodore Friedmann Carl W. Schmid Prescott L. Deininger Carol M. Rubin Inder M. Verma A. Dusty Miller Thomas W. Dubensky Sybille L. Sauter
Topics: Virus-based gene therapy research (63 papers)CRISPR and Genetic Engineering (24 papers)Biochemical and Molecular Research (19 papers)
Cited by: Genetics Virology Molecular Biology
Journals: Science Proceedings of the National Academy of Sciences Nucleic Acids Research
Partner nations: United States United Kingdom Japan

In The Last Decade

Douglas J. Jolly

103 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Base sequence studies of 300 nucleotide renatured repeated human DNA clones

1981 558 citations Douglas J. Jolly et al. profile →

Peers

Countries citing papers authored by Douglas J. Jolly

Since Specialization

Citations

This map shows the geographic impact of Douglas J. Jolly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas J. Jolly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas J. Jolly more than expected).

Fields of papers citing papers by Douglas J. Jolly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas J. Jolly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas J. Jolly. The network helps show where Douglas J. Jolly may publish in the future.

Co-authorship network of co-authors of Douglas J. Jolly

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas J. Jolly. A scholar is included among the top collaborators of Douglas J. Jolly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas J. Jolly. Douglas J. Jolly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model 2024 ·Cancer Gene Therapy ·(unknown),Toru Nakamura,(unknown),(unknown),(unknown),Akihito Inagaki,Tomohiro Suzuki,Katsunori Sasaki,Takahiro Tsuchikawa,Kei Hiraoka,Toshiaki Shichinohe,Yutaka Hatanaka,Douglas J. Jolly,Noriyuki Kasahara,Satoshi Hirano	1
2	Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer 2021 ·Expert Opinion on Biological Therapy ·Sara Collins,Ashish H. Shah,Derek Ostertag,Noriyuki Kasahara,Douglas J. Jolly	21
3	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma 2020 ·Clinical Cancer Research ·William P. Accomando,(unknown),Daniel J. Hogan,Aaron M. Newman,(unknown),Ash A. Alizadeh,Maximilian Diehn,Oscar R. Diago,Dawn Gammon,Ali Haghighi,Harry E. Gruber,Douglas J. Jolly,Derek Ostertag	17
4	Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients 2018 ·Clinical Cancer Research ·Daniel J. Hogan,Jay‐Jiguang Zhu,Oscar R. Diago,Dawn Gammon,Ali Haghighi,Guangrong Lu,Asha Das,Harry E. Gruber,Douglas J. Jolly,Derek Ostertag	23
5	Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer 2018 ·Cancer Gene Therapy ·(unknown),Kei Hiraoka,Akihito Inagaki,(unknown),Toshihiro Kushibiki,(unknown),(unknown),(unknown),(unknown),Toru Nakamura,Takahiro Tsuchikawa,Toshiaki Shichinohe,Harry E. Gruber,Douglas J. Jolly,Noriyuki Kasahara,Satoshi Hirano	14
6	Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model 2017 ·Neuro-Oncology ·Leah Mitchell,(unknown),Daniel Mendoza,(unknown),Akihito Inagaki,Kei Hiraoka,Noriyuki Kasahara,Harry E. Gruber,Douglas J. Jolly,Joan M. Robbins	69
7	Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene 2016 ·Human Gene Therapy Methods ·Amy Lin,Yanzheng Liu,(unknown),(unknown),Christopher R. Logg,Joan M. Robbins,Noriyuki Kasahara,Harry E. Gruber,Carlos E. Ibañez,Douglas J. Jolly	3
8	Intravenous Administration of Retroviral Replicating Vector, Toca 511, Demonstrates Therapeutic Efficacy in Orthotopic Immune-Competent Mouse Glioma Model 2014 ·Human Gene Therapy ·Tiffany Huang,(unknown),Ryan Burnett,Oscar R. Diago,Derek Ostertag,Florence M. Hofman,(unknown),(unknown),Carlos E. Ibañez,Noriyuki Kasahara,Harry E. Gruber,(unknown),Douglas J. Jolly,Joan M. Robbins	49
9	Not Reinventing the Wheel: Applying the 3Rs Concepts to Viral Vector Gene Therapy Biodistribution Studies 2013 ·PubMed ·Timothy K. MacLachlan,(unknown),Kyriacos Mitrophanous,James Miskin,Douglas J. Jolly,Joy Cavagnaro	4
10	Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model 2013 ·Cancer Gene Therapy ·Dong Yin,You Zhai,Harry E. Gruber,Carlos E. Ibañez,Joan M. Robbins,Adrian P. Kells,Noriyuki Kasahara,John Forsayeth,Douglas J. Jolly,Krys S. Bankiewicz	21
11	Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model 2013 ·Cancer Gene Therapy ·Tiffany Huang,Juraj Hlavatý,Derek Ostertag,(unknown),(unknown),Helga Petznek,Maria E. Rodriguez-Aguirre,Carlos E. Ibañez,Noriyuki Kasahara,Walter H. Günzburg,Harry E. Gruber,(unknown),Douglas J. Jolly,Joan M. Robbins	45
12	Retroviral Replicating Vectors in Cancer 2012 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Christopher R. Logg,Joan M. Robbins,Douglas J. Jolly,Harry E. Gruber,Noriyuki Kasahara	18
13	Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector 2011 ·Neuro-Oncology ·Derek Ostertag,Karin Amundson,(unknown),(unknown),(unknown),Ana Paula da Silva,A. Lin,David T. Valenta,(unknown),Carlos E. Ibañez,(unknown),Pär L. Pettersson,Ryan Burnett,(unknown),Juraj Hlavatý,Walter H. Günzburg,Noriyuki Kasahara,Harry E. Gruber,Douglas J. Jolly,Joan M. Robbins	110
14	Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors 2000 ·Neuroreport ·Joseph Martín Alisky,Stephanie M. Hughes,Sybille L. Sauter,Douglas J. Jolly,Thomas W. Dubensky,Patrick D. Staber,John A. Chiorini,Beverly L. Davidson	121
15	Generation of Retroviral Packaging and Producer Cell Lines for Large-Scale Vector Production and Clinical Application: Improved Safety and High Titer 2000 ·Molecular Therapy ·Philip L. Sheridan,Mordechai Bodner,(unknown),(unknown),Nicholas J. DePolo,(unknown),(unknown),Kathy Nguyen,James E. McCormack,David A. Driver,Kay Townsend,Carlos E. Ibañez,Nancy Sajjadi,Judith S. Greengard,Margaret Moore,James Respess,Stephen M. W. Chang,Thomas W. Dubensky,Douglas J. Jolly,Sybille L. Sauter	49
16	Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients 2000 ·Cancer Gene Therapy ·Shigeyuki Fujii,Sharon K. Huang,(unknown),Dale Ando,Francis Burrows,Douglas J. Jolly,John Nemunaitis,Dave S.�B. Hoon	33
17	Use of a recombinant murine cytomegalovirus expressing vesicular stomatitis virus G protein to pseudotype retroviral vectors 1998 ·Journal of Virological Methods ·William C. Manning,John E. Murphy,Douglas J. Jolly,Steven J. Mento,Robert Ralston	10
18	Cytotoxic T Lymphocyte and Antibody Responses Generated in Rhesus Monkeys Immunized with Retroviral Vector-Transduced Fibroblasts Expressing Human Immunodeficiency Virus Type-1 IIIB ENV/REV Proteins 1994 ·Human Gene Therapy ·(unknown),Michelle Burrascano,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Kay Townsend,(unknown),Douglas J. Jolly,Bruce Merchant,John F. Warner	21
19	CTL Cross Reactivity Between HIV Strains 1992 ·AIDS Research and Human Retroviruses ·Douglas J. Jolly,Sunil Chada,Kay Townsend,(unknown),S M Chang,Kent J. Weinhold,(unknown),(unknown),Mordechai Bodner,(unknown),John F. Warner	2
20	[Comparative study of antitoxoplasmic IgG isotypes titrated by high sensitivity direct agglutination and indirect immunofluorescence: consequence of the choice of methods on the expression of results in international units]. 1990 ·PubMed ·(unknown),Douglas J. Jolly,Odile Bajolet,(unknown),(unknown),A. Bonhomme,F. Blanchard,J. M. Pinon	4

About Douglas J. Jolly

Douglas J. Jolly is a scholar working on Virology, Genetics and Biotechnology, having authored 108 papers that have together received 4.8k indexed citations. Recurring topics across this work include Virus-based gene therapy research (63 papers), CRISPR and Genetic Engineering (24 papers) and Biochemical and Molecular Research (19 papers). The work is most often cited by research in Genetics (2.5k citations), Virology (245 citations) and Molecular Biology (3.3k citations). Douglas J. Jolly has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Theodore Friedmann, Carl W. Schmid, Prescott L. Deininger, Carol M. Rubin, Inder M. Verma, A. Dusty Miller, Thomas W. Dubensky, Sybille L. Sauter, Harry E. Gruber and Henryk Eisenberg. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact